Literature DB >> 14163957

PROGRESS IN CHEMOTHERAPY OF CANCER.

W DAVIS, L F LARIONOV.   

Abstract

The chemotherapy of cancer, in relation to surgery and radiotherapy, is a new method of attack. Its development, which started virtually in the 1940's, was reviewed by the WHO Expert Committee on Chemotherapy of Cancer that met in September 1961. The report of the Committee dealt with experimental and clinical studies in this field critically, but also to a necessary degree, comprehensively. The design and mechanism of action of the drugs, their biological screening and subsequent clinical trials were discussed, and a review was presented of the clinically available drugs and the neoplasms for which they were indicated. In the two years that have elapsed since the report was drawn up many new compounds have been tested and some have had clinical trials. There have been developments, too, in methods of administration. All these new developments are discussed in the present paper.

Entities:  

Keywords:  ALKALOIDS; ANTIBIOTICS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CERVIX NEOPLASMS; ESOPHAGEAL NEOPLASMS; EXPERIMENTAL LAB STUDY; GASTROINTESTINAL NEOPLASMS; HORMONES; INFUSIONS, PARENTERAL; ISOLATION PERFUSION; LUNG NEOPLASMS; NEOPLASM RADIOTHERAPY; NEOPLASM THERAPY; RESEARCH; REVIEW; SEROTHERAPY; SURGERY, OPERATIVE

Mesh:

Substances:

Year:  1964        PMID: 14163957      PMCID: PMC2554827     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  48 in total

1.  4,6-DIAMINO-1-ALKYL-1,2-DIHYDRO-S-TRIAZINES.

Authors:  J G LOMBARDINO
Journal:  J Med Chem       Date:  1963-03       Impact factor: 7.446

2.  PARA-(N-BIS-(2-CHLOROETHYL))-AMINOBENZOYLGLUTAMIC ACID.

Authors:  S C FU
Journal:  J Med Pharm Chem       Date:  1962-01

3.  STRUCTURE-ACTIVITY RELATIONSHIPS OF ETHYLENIMINES. II. METHYL- SUBSTITUTED DERIVATIVES OF TETRAMIN.

Authors:  A T BOTTINI; V DEV
Journal:  J Med Pharm Chem       Date:  1962-09

4.  DIHYDRO-1,3-OXAZINES AS ANTITUMOR AGENTS.

Authors:  M E KUEHNE; E A KONOPKA
Journal:  J Med Pharm Chem       Date:  1962-03

5.  SYNTHESIS AND ANTITUMOR ACTIVITY OF 2-AMINO-1-METHYLPURINE- 6-THIONE.

Authors:  C W NOELL; D W SMITH; R K ROBINS
Journal:  J Med Pharm Chem       Date:  1962-09

6.  Autoradiographic studies of in vitro incorporation of uridine and thymidine by human tumor tissue.

Authors:  W H WOLBERG; R R BROWN
Journal:  Cancer Res       Date:  1962-10       Impact factor: 12.701

7.  Studies on carcinostatic substances. XLI. Preparation of azide derivatives of 1,1-bis(2-chloroethyl)hydrazine.

Authors:  Y SAKURAI; M AOSHIMA
Journal:  Chem Pharm Bull (Tokyo)       Date:  1962-10       Impact factor: 1.645

8.  Massive intra-aortic injections of nitrogen mustard (Dichloren), 5-fluorouracil, nitromin, and endoxan prior to roentgen irradiation for advanced tumors of the uterus.

Authors:  M RIEBELING
Journal:  Radiology       Date:  1962-07       Impact factor: 11.105

9.  SYNTHESIS OF N-PHOSPHORYLATED DERIVATIVES OF NITROGEN MUSTARDS WITH LATENT CYTOTOXICITY.

Authors:  O M FRIEDMAN; E BOGER; V GRUBLIAUSKAS; H SOMMER
Journal:  J Med Chem       Date:  1963-01       Impact factor: 7.446

10.  THE SYNTHESIS AND ANTINEOPLASTIC PROPERTIES OF SELENOGUANINE, SELENOCYTOSINE AND RELATED COMPOUNDS.

Authors:  H G MAUTNER; S H CHU; J J JAFFE; A C SARTORELLI
Journal:  J Med Chem       Date:  1963-01       Impact factor: 7.446

View more
  3 in total

1.  Dysphagia predict the response to second cycle neoadjuvant chemotherapy in first cycle no response esophageal carcinoma.

Authors:  Yan Zheng; Yin Li; Jianjun Qin; Wenqun Xing; Xianben Liu; Haibo Sun; Xiankai Chen
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 2.  Advances in Radiotherapy Management of Esophageal Cancer.

Authors:  Vivek Verma; Amy C Moreno; Steven H Lin
Journal:  J Clin Med       Date:  2016-10-21       Impact factor: 4.241

Review 3.  Role of the oral microbiota in cancer evolution and progression.

Authors:  Jiwei Sun; Qingming Tang; Shaoling Yu; Mengru Xie; Yanling Xie; Guangjin Chen; Lili Chen
Journal:  Cancer Med       Date:  2020-07-07       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.